Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCOLN3 | Q8TDD5 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.88 |
| ▸ | PKM | P14618 | 6/20 | 0.73 |
| ▸ | LMNA | P02545 | 4/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | PKLR | P30613 | 1/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30821997 | 1.00 | MCOLN3 (1.00) | MCOLN3TSHRMEN1KMT2APKM | |
| SCHEMBL3169939 | 0.98 | MCOLN3 (0.97) | MCOLN3TSHRMEN1KMT2APKM | |
| SCHEMBL18134604 | 0.91 | MCOLN3 (0.83) | MCOLN3TSHRMEN1KMT2APKM | |
| SCHEMBL8365545 | 0.85 | MCOLN3 (0.73) | MCOLN3TSHRMEN1KMT2APKM | |
| SCHEMBL6793698 | 0.85 | PKM (0.89) | MCOLN3TSHRMEN1KMT2APKM | |
| SCHEMBL15014129 | 0.83 | PKM (0.89) | MCOLN3TSHRMEN1KMT2APKM | |
| SCHEMBL29483657 | 0.83 | PKM (0.89) | MCOLN3TSHRMEN1KMT2APKM | |
| SCHEMBL20021982 | 0.83 | PKM (0.89) | MCOLN3TSHRMEN1KMT2APKM | |
| SCHEMBL1048996 | 0.83 | MCOLN3 (0.71) | MCOLN3TSHRMEN1KMT2APKM | |
| SCHEMBL12655865 | 0.83 | MCOLN3 (0.71) | MCOLN3TSHRMEN1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093960-A1 | METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2018-04-05 | — | — | US | disclosed |
| US-20180093960-A1 | METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2018-04-05 | — | — | US | disclosed |
| EP-1089988-B1 | FLUOROPHENYL RESIN COMPOUNDS | AVENTIS PHARMA INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-7276524-B2 | Pyridyl alkane acid amides as cytostatics and immunosuppressives | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-10-02 | — | — | US | disclosed |
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | ASTELLAS PHARMA GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-7241745-B2 | Pyridyl alkene and pyridyl alkine acid amides as cytostatics and immunosupressives | ASTELLAS PHARMA GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-20070142377-A1 | Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives | BIEDERMANN ELFI | 2007-06-21 | — | — | US | disclosed |
| EP-1089988-A4 | FLUOROPHENYL RESIN COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2005-01-19 | — | — | EP | disclosed |
| CN-1185259-C | Fluorophenyl resin compounds | AVENTIES PHARMACEUTICALS INC (US) | 2005-01-19 | — | — | CN | disclosed |
| CN-1306524-A | Fluorophenyl resin compounds | AVENTIES PHARMACEUTICALS INC (US) | 2001-08-01 | — | — | CN | disclosed |
| EP-1089988-A1 | FLUOROPHENYL RESIN COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067228-A1 | FLUOROPHENYL RESIN COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093960-A1 | METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND | LDLR, APOB, NR1H2 | MCOLN3 4614/4885TSHR 1808/4885MEN1 4593/4885 |
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | NFATC1, PDCD1, ACIN1 | MCOLN3 3990/4885TSHR 3222/4885MEN1 2546/4885 |
| US-20070142377-A1 | Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives | ALK, TYMP, PDCD1 | MCOLN3 3882/4885TSHR 2552/4885MEN1 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.